Carregant...
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure
AIM: First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [T(c >0.05)]). Second, screen additional pharmacogenes for associations with T(c >0.05). METHODS: Pharmacogene panel gen...
Guardat en:
| Publicat a: | Pharmacogenomics |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Medicine Ltd
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6562943/ https://ncbi.nlm.nih.gov/pubmed/30520341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2018-0162 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|